Anticancer Drugs Practice Questions

Q: The figure shows the mechanism of action of which of the following drugs?

Nilotinib. ***Nilotinib*** - **Second-generation tyrosine kinase inhibitor** that specifically targets **BCR-ABL** fusion protein in chronic myeloid leukemia (CML). - Binds to the **ATP-binding site** of BCR-ABL kinase, blocking its autophosphorylation and downstream signaling pathways that promote cell proliferation. *Methotrexate* - Acts as a **dihydrofolate reductase (DHFR) inhibitor**, preventing conversion of dihydrofolate to tetrahydrofolate. - Mechanism involves **folate antagonism**, not tyrosine kinase inhibition, disrupting **DNA synthesis** and **purine metabolism**. *Pertuzumab* - **Monoclonal antibody** that binds to **HER2 receptor**, preventing **heterodimerization** with other HER family receptors. - Mechanism involves **receptor blockade** rather than kinase inhibition, primarily used in **HER2-positive breast cancer**. *Cisplatin* - **Platinum-based alkylating agent** that forms **DNA cross-links** between and within DNA strands. - Mechanism involves **DNA damage** and **apoptosis induction**, not kinase pathway interference like tyrosine kinase inhibitors.

Q: Which of the following antineoplastic drugs causes hepatotoxicity?

6-mercaptopurine. **Explanation:** **6-Mercaptopurine (6-MP)** is a thiopurine antimetabolite that acts as a purine analogue. It is a well-known cause of **hepatotoxicity**, which typically manifests as cholestatic jaundice, elevated transaminases, or even hepatic necrosis. The toxicity is often dose-related and is linked to its metabolism by the enzyme **Thiopurine Methyltransferase (TPMT)**. Patients with genetic deficiencies in TPMT are at a significantly higher risk of severe bone marrow suppression and hepatotoxicity when treated with standard doses of 6-MP or its prodrug, Azathioprine. **Analysis of Incorrect Options:** * **5-Fluorouracil (5-FU):** Primarily associated with gastrointestinal toxicity (mucositis, diarrhea) and **Hand-Foot Syndrome** (palmar-plantar erythrodysesthesia). It is not typically associated with significant hepatotoxicity. * **Doxorubicin:** An anthracycline antibiotic famous for its **cardiotoxicity** (dilated cardiomyopathy) due to free radical generation. Its main dose-limiting toxicity is myelosuppression. * **Etoposide:** A topoisomerase II inhibitor. Its primary adverse effects are myelosuppression and alopecia; it is also associated with a risk of secondary leukemia. **High-Yield NEET-PG Pearls:** * **TPMT Testing:** Always screen for TPMT activity before starting 6-MP to prevent life-threatening toxicity. * **Drug Interaction:** **Allopurinol** inhibits Xanthine Oxidase (the enzyme that degrades 6-MP). Co-administration leads to toxic levels of 6-MP; therefore, the dose of 6-MP must be reduced by 50-75%. * **Other Hepatotoxic Chemo Agents:** Methotrexate (cirrhosis/fibrosis), L-asparaginase, and Busulfan (Veno-occlusive disease).

Q: Stocking and glove neuropathy is seen in which of the following chemotherapeutic agents?

Paclitaxel. **Explanation:** **Correct Option: B (Paclitaxel)** Paclitaxel, a taxane, acts by stabilizing microtubules and preventing their disassembly (arresting cells in the M-phase). Its most characteristic dose-limiting toxicity is **peripheral neuropathy**, typically presenting in a **"stocking and glove" distribution**. This occurs because taxanes interfere with microtubule-dependent axonal transport, leading to distal axonal degeneration. Sensory symptoms (numbness, tingling, and burning pain) usually precede motor involvement. **Analysis of Incorrect Options:** * **A. Vinblastine:** While Vinca alkaloids (like Vincristine) are notorious for neurotoxicity, Vinblastine is primarily associated with **bone marrow suppression** (Vin**b**lastine **b**lasts the **b**one marrow). Vincristine is more commonly linked to peripheral neuropathy than Vinblastine. * **C. Etoposide:** This is a Topoisomerase II inhibitor. Its major side effects are myelosuppression and alopecia. It is also associated with an increased risk of secondary leukemia. * **D. Mitoxantrone:** An anthracenedione used in prostate cancer and MS. Its primary concern is **cardiotoxicity** (though less than Doxorubicin) and it can cause a harmless blue-green discoloration of urine and sclera. **High-Yield Clinical Pearls for NEET-PG:** * **Microtubule Inhibitors:** Remember "Vincas prevent assembly, Taxanes prevent disassembly." * **Other drugs causing Peripheral Neuropathy:** Vincristine, Cisplatin, Oxaliplatin (cold-induced), Thalidomide, and Bortezomib. * **Paclitaxel Pre-medication:** To prevent hypersensitivity reactions (due to the Cremophor EL vehicle), patients are pre-treated with Dexamethasone, H1 blockers, and H2 blockers.

Q: Which of the following immunosuppressive agents acts primarily by inhibiting helper T cells?

Cyclosporine. **Explanation:** **Correct Answer: A. Cyclosporine** Cyclosporine is a potent immunosuppressant classified as a **Calcineurin Inhibitor**. Its primary mechanism involves binding to the intracellular protein **Cyclophilin**. This complex inhibits Calcineurin, a phosphatase required for the dephosphorylation and activation of the **Nuclear Factor of Activated T-cells (NFAT)**. Consequently, the transcription of **Interleukin-2 (IL-2)** is blocked. Since IL-2 is the primary cytokine responsible for the proliferation and activation of **Helper T-cells (CD4+ cells)**, Cyclosporine effectively suppresses T-cell-mediated immunity. **Analysis of Incorrect Options:** * **B. Azathioprine:** This is a purine antimetabolite (prodrug of 6-Mercaptopurine). It inhibits DNA synthesis, affecting the proliferation of both T and B lymphocytes non-specifically, rather than acting primarily as a signaling inhibitor in helper T-cells. * **C. Cytarabine:** An antimetabolite (Pyrimidine analog) used primarily in chemotherapy for Acute Myeloid Leukemia (AML). It inhibits DNA polymerase and is not used as a primary immunosuppressant for T-cell inhibition. * **D. Cycloserine:** An antitubercular drug (second-line) that inhibits bacterial cell wall synthesis by acting as an analog of D-alanine. It has no role in immunosuppression. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of Cyclosporine:** Remember the "5 H's"—**H**irsutism, **H**yperplasia of gums (gingival hypertrophy), **H**ypertension, **H**yperlipidemia, and **H**epatotoxicity. It is also notably **Nephrotoxic**. * **Drug Interactions:** Cyclosporine is metabolized by **CYP3A4**; its levels increase with Grapefruit juice and Macrolides. * **Comparison:** Unlike Cyclosporine, **Tacrolimus** binds to **FKBP-12** but shares the same mechanism of inhibiting Calcineurin. Tacrolimus does *not* cause hirsutism or gingival hyperplasia.

Q: Which antimetabolite antineoplastic agent is used in the treatment of mesothelioma?

Pemetrexed. **Explanation:** **Pemetrexed** is the correct answer. It is a multi-targeted antifolate antimetabolite that inhibits three key enzymes in folate metabolism: **thymidylate synthase (TS)**, **dihydrofolate reductase (DHFR)**, and **glycinamide ribonucleotide formyltransferase (GARFT)**. Its primary clinical indication is in the treatment of **malignant pleural mesothelioma** (in combination with Cisplatin) and non-small cell lung cancer (NSCLC). **Analysis of Incorrect Options:** * **A. 6-thioguanine:** A purine analog used primarily in the treatment of acute leukemias (AML). It does not have a role in solid tumors like mesothelioma. * **B. 5-FU (5-Fluorouracil):** A pyrimidine analog used extensively for GI tract cancers (colorectal, gastric) and breast cancer, but it is not the standard of care for mesothelioma. * **C. Busulfan:** An **alkylating agent** (specifically an alkyl sulfonate), not an antimetabolite. It is primarily used in chronic myeloid leukemia (CML) and as a conditioning agent before bone marrow transplantation. **High-Yield Clinical Pearls for NEET-PG:** * **Supplementation:** To reduce the hematologic and GI toxicity of Pemetrexed, patients must be pre-treated with **Vitamin B12 and Folic Acid**. * **Skin Reactions:** Dexamethasone is often given to prevent the cutaneous rash associated with Pemetrexed. * **Mechanism:** Unlike Methotrexate (which primarily inhibits DHFR), Pemetrexed’s inhibition of TS and GARFT makes it more effective against a broader range of solid tumors. * **Drug of Choice:** Pemetrexed + Cisplatin is the first-line chemotherapy regimen for unresectable mesothelioma.

Q: Coasting effect is seen with which of the following agents?

Platinum compounds. **Explanation:** The **"Coasting Effect"** refers to a unique clinical phenomenon where neurotoxicity (specifically peripheral sensory neuropathy) continues to progress or worsen for several weeks to months even after the offending drug has been discontinued. **1. Why Platinum Compounds are correct:** Platinum-based agents, most notably **Oxaliplatin** (and to a lesser extent Cisplatin), are the classic cause of the coasting effect. These drugs accumulate in the dorsal root ganglia. Due to their slow clearance from neuronal tissues, DNA damage and oxidative stress continue to evolve even after plasma levels drop. Patients may report worsening numbness, tingling, or pain long after their final chemotherapy cycle. **2. Why the other options are incorrect:** * **Nitrogen mustards (e.g., Cyclophosphamide):** Their primary dose-limiting toxicity is myelosuppression and hemorrhagic cystitis. While they can cause some neurotoxicity (Ifosfamide), they do not typically exhibit the coasting phenomenon. * **Methotrexate:** Known for myelosuppression, mucositis, and hepatotoxicity. While intrathecal use can cause leucoencephalopathy, it does not cause the delayed sensory "coasting" seen with platinums. * **Dacarbazine:** Primarily causes severe nausea/vomiting and myelosuppression. It is not associated with progressive delayed neuropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Oxaliplatin:** Distinctive for **cold-induced dysesthesia** (exacerbated by cold drinks/weather). * **Cisplatin:** Notable for **ototoxicity** (high-frequency hearing loss) and **nephrotoxicity** (prevented by aggressive hydration and Amifostine). * **Vinca Alkaloids (Vincristine):** Also cause peripheral neuropathy, but unlike platinums, the symptoms usually stabilize or improve relatively quickly upon discontinuation rather than "coasting."

Q: Which of the following anticancer drugs is least likely to cause nausea and vomiting?

Chlorambucil. **Explanation:** The emetogenic potential of chemotherapy is a high-yield topic for NEET-PG. Anticancer drugs are classified into four categories based on their risk of causing nausea and vomiting: High (>90%), Moderate (30–90%), Low (10–30%), and Minimal (<10%). **1. Why Chlorambucil is correct:** Chlorambucil is an oral alkylating agent (nitrogen mustard) used primarily in Chronic Lymphocytic Leukemia (CLL). It is classified as having **minimal emetogenic potential** ( 90% risk). It triggers both acute and delayed emesis by releasing serotonin from enterochromaffin cells and acting on the Chemoreceptor Trigger Zone (CTZ). * **Doxorubicin & Daunorubicin (Options C & D):** These anthracyclines are classified as having **moderate emetogenic potential** (30–90% risk). When combined with cyclophosphamide (AC regimen), they are treated as highly emetogenic. **NEET-PG High-Yield Pearls:** * **Highest Emetogenic Potential:** Cisplatin (most common answer), Dacarbazine, and high-dose Cyclophosphamide. * **Drug of Choice for Cisplatin-induced vomiting:** 5-HT3 antagonists (e.g., Ondansetron) are used for acute emesis; NK1 receptor antagonists (e.g., Aprepitant) are added for delayed emesis. * **Least Emetogenic Agents:** Vincristine, Bleomycin, Busulfan, and Chlorambucil. * **Anticipatory Vomiting:** Best managed with Benzodiazepines (e.g., Lorazepam).

Q: Bleomycin toxicity is characterized by hyperplasia of which of the following cells?

Type II pneumocytes. **Explanation:** **Bleomycin** is a cytotoxic antibiotic that causes DNA strand scission through free radical generation. Its most significant dose-limiting toxicity is **Pulmonary Fibrosis**. **Why Type II Pneumocytes?** The pathogenesis of Bleomycin-induced lung injury involves damage to the alveolar epithelium. Bleomycin causes oxidative stress and damage to **Type I pneumocytes** (which cover 95% of the alveolar surface). In a compensatory attempt to repair the alveolar basement membrane, **Type II pneumocytes undergo hyperplasia** and hypertrophy. However, they fail to differentiate effectively into Type I cells, leading to fibroblast activation and subsequent interstitial fibrosis. This "Type II pneumocyte hyperplasia" is a hallmark histopathological finding. **Analysis of Incorrect Options:** * **A. Endothelial cells:** While bleomycin can cause initial vascular leakage, it does not typically cause endothelial hyperplasia. * **B. Type I pneumocytes:** These cells are extremely sensitive to injury and are **destroyed** (necrosed) by bleomycin, not increased in number. * **D. Alveolar macrophages:** While macrophages are involved in the inflammatory cytokine cascade (TGF-beta), they do not undergo characteristic hyperplasia in this context. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Chelates ferrous iron ($Fe^{2+}$) to form free radicals. * **Cell Cycle:** Specifically acts on the **G2 phase**. * **Metabolism:** Inactivated by **bleomycin hydrolase**. The lung and skin have low levels of this enzyme, explaining the site-specific toxicities (Pulmonary fibrosis and Skin hyperpigmentation/flagellate dermatitis). * **Monitoring:** Pulmonary Function Tests (PFTs) showing a **decrease in DLCO** (Diffusion capacity) is the earliest sign of toxicity. * **Risk Factor:** High inspired oxygen ($FiO_2$) during surgery can exacerbate bleomycin lung injury.

Q: Which of the following is a monoclonal antibody against PD-L1?

Durvalumab. Explanation: Durvalumab is a human monoclonal antibody that targets Programmed Death-Ligand 1 (PD-L1). In the tumor microenvironment, cancer cells express PD-L1, which binds to PD-1 receptors on T-cells, effectively "switching off" the immune response (immune checkpoint). By inhibiting PD-L1, Durvalumab restores T-cell mediated anti-tumor activity. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma. Analysis of Incorrect Options: * Golimumab (A): A monoclonal antibody against TNF-alpha. It is used in the management of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. * Guselkumab (B): An interleukin inhibitor that targets IL-23. It is specifically indicated for moderate-to-severe plaque psoriasis. * Vedolizumab (D): An integrin antagonist (specifically $\alpha_4\beta_7$ integrin) [1]. It is gut-selective and used in the treatment of Inflammatory Bowel Disease (Crohn’s disease and Ulcerative Colitis) [1]. High-Yield NEET-PG Pearls: * PD-1 Inhibitors: Nivolumab, Pembrolizumab, and Cemiplimab (Target the receptor on T-cells). * PD-L1 Inhibitors: Atezolizumab, Avelumab, and Durvalumab (Mnemonic: "AAD" targets the Ligand on tumor cells). * CTLA-4 Inhibitor: Ipilimumab (another major immune checkpoint inhibitor). * Suffix Tip: Monoclonal antibodies ending in "-umab" are fully human, reducing the risk of infusion reactions compared to chimeric ("-ximab") antibodies.

Q: What is the standard chemotherapy regimen for metastatic testicular carcinoma?

Bleomycin, Etoposide, Cisplatin. **Explanation:** The standard of care for metastatic germ cell tumors, including testicular carcinoma, is the **BEP regimen**. This combination is highly effective, often achieving cure rates exceeding 90% even in advanced stages. **1. Why Option A is Correct:** The BEP regimen consists of: * **B**leomycin (Antitumor antibiotic): Causes DNA strand breaks. * **E**toposide (Topoisomerase II inhibitor): Prevents DNA replication. * **P**latin (**Cisplatin**): An alkylating-like agent that forms DNA cross-links. Cisplatin is the "backbone" of this therapy. The synergy between these drugs targets rapidly dividing germ cells at different phases of the cell cycle. **2. Analysis of Incorrect Options:** * **Option B (VEP):** While Vinblastine was historically used (VBP regimen), it has been largely replaced by Etoposide because Etoposide offers better efficacy and lower neurotoxicity. * **Option C:** This combination is not a standard regimen. Doxorubicin and 5-FU are more commonly associated with breast or GI cancers. * **Option D:** These drugs are used in various protocols (like for ALL or colorectal cancer) but lack the specific efficacy required for testicular germ cell tumors. **3. NEET-PG High-Yield Pearls:** * **Toxicity Profile:** * **Bleomycin:** Pulmonary fibrosis (monitor with DLCO). It is "skin and lung" toxic but **bone marrow sparing**. * **Cisplatin:** Nephrotoxicity (prevent with aggressive hydration/Amifostine) and Ototoxicity. * **Etoposide:** Secondary malignancies (specifically AML). * **Tumor Markers:** Always correlate treatment with Beta-hCG, AFP, and LDH levels. * **Alternative:** If Bleomycin is contraindicated (e.g., pre-existing lung disease), the **VIP regimen** (Etoposide, Ifosfamide, Cisplatin) is used.

Question 1

The figure shows the mechanism of action of which of the following drugs?

Accepted Answer

Nilotinib

Answer

Methotrexate

Answer

Pertuzumab

Answer

Cisplatin

Question 2

Which of the following antineoplastic drugs causes hepatotoxicity?

Accepted Answer

6-mercaptopurine

Answer

5-fluorouracil

Answer

Doxorubicin

Answer

Etoposide

Question 3

Stocking and glove neuropathy is seen in which of the following chemotherapeutic agents?

Accepted Answer

Paclitaxel

Answer

Vinblastine

Answer

Etoposide

Answer

Mitoxantrone

Question 4

Which of the following immunosuppressive agents acts primarily by inhibiting helper T cells?

Accepted Answer

Cyclosporine

Answer

Azathioprine

Answer

Cytarabine

Answer

Cycloserine

Question 5

Which antimetabolite antineoplastic agent is used in the treatment of mesothelioma?

Accepted Answer

Pemetrexed

Answer

6-thioguanine

Answer

5-FU

Answer

Busulfan

Question 6

Coasting effect is seen with which of the following agents?

Accepted Answer

Platinum compounds

Answer

Nitrogen mustards

Answer

Methotrexate

Answer

Dacarbazine

Question 7

Which of the following anticancer drugs is least likely to cause nausea and vomiting?

Accepted Answer

Chlorambucil

Answer

Cisplatin

Answer

Doxorubicin

Answer

Daunorubicin

Question 8

Bleomycin toxicity is characterized by hyperplasia of which of the following cells?

Accepted Answer

Type II pneumocytes

Answer

Endothelial cells

Answer

Type I pneumocytes

Answer

Alveolar macrophages

Question 9

Which of the following is a monoclonal antibody against PD-L1?

Accepted Answer

Durvalumab

Answer

Golimumab

Answer

Guselkumab

Answer

Vedolizumab

Question 10

What is the standard chemotherapy regimen for metastatic testicular carcinoma?

Accepted Answer

Bleomycin, Etoposide, Cisplatin

Answer

Vinblastine, Etoposide, Cisplatin

Answer

Doxorubicin, 5-Fluorouracil, Mercaptopurine

Answer

Methotrexate, 5-Fluorouracil, Vincristine

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?